Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01
14 févr. 2024 06h00 HE
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an...
Palisade Bio Provides Corporate Update and Reiterates Guidance
13 févr. 2024 08h35 HE
|
Palisade Bio, Inc.
– Company announces strategic streamlining of Board to align with the current state of clinical development and corporate vision – Advancement of PALI-2108 for the treatment of moderate-to-severe...
Correction Notice of Palisade Bio’s Press Release Announcing the Appointment of Clinical Advisory Board Members
08 févr. 2024 14h40 HE
|
Palisade Bio, Inc.
Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for...
Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders
08 févr. 2024 08h05 HE
|
Palisade Bio, Inc.
Bruce Sands, MD, MS., Dr. Burrill B. Crohn Professor of Medicine, Icahn School of Medicine at Mount Sinai and System Chief, Division of Gastroenterology, Mount Sinai Health SystemFlorian Rieder, MD,...
QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals
07 févr. 2024 16h00 HE
|
QSAM Biosciences Inc.
Austin, TX, Feb. 07, 2024 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM) (“QSAM or the “Company”) has signed a definitive Agreement and Plan of Merger (the “Agreement”) providing for the...
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split
01 févr. 2024 11h00 HE
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), a clinical stage immuno-oncology company focused on developing innovative therapeutics...
Palisade Bio Announces Exercise of Previously Issued Warrants for $2.5 Million
30 janv. 2024 09h25 HE
|
Palisade Bio, Inc.
Carlsbad, CA, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for...
Palisade Bio Selected for Poster Presentation at the 2024 Crohn’s & Colitis Congress
09 janv. 2024 08h00 HE
|
Palisade Bio, Inc.
Carlsbad, CA, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious...
Hepion Pharmaceuticals to Present at NASH-TAG 2024
03 janv. 2024 17h15 HE
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Visiox Pharmaceuticals, Inc., a Commercial-Stage Biopharmaceutical Company to be Listed on Nasdaq Through a Business Combination with PowerUp Acquisition Corp.
27 déc. 2023 08h01 HE
|
PowerUp Acquisition Corp.
Tarrytown, NY and New York, NY, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Visiox Pharmaceuticals, Inc. (“Visiox” or the “Company”), a commercial-stage biopharmaceutical company, and PowerUp Acquisition...